A5225: Phase I/II Dose-Finding Study of High-Dose Fluconazole Treatment in AIDS-Associated Cryptococcal Meningitis

Post Date: 
2009-04-22
   |   
Countries: 
   |   
Clinical Sites: 
Summary: 

This trial was terminated in March 2015; it was conducted under the AIDS Clinical Trials Group (ACTG) and funded by the U.S. National Institutes of Health.

This multi-country study was conducted in India, Kenyam Peru, South Africa, Thailand, Uganda, United States, and Zimbabwe.

A5225/HiFLAC is a Phase I/II dose escalation and validation study of the safety, tolerability, and therapeutic effect of an induction-consolidation strategy of high-dose fluconazole alone for the treatment of cryptococcal meningitis (CM) in HIV-infected participants.